Steven Schepens, MD
Family Medicine · Gulfport, MSNPI 1982719779
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 751 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 11.1% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 751 payments — averaging $15.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$1K
- GSK$1K
- Lilly USA, LLC$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$909
- AstraZeneca$770
- plus $6K from 34 others
What the payments were for
- Food & beverage$11,82499%
- Education$1471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$11,971 in reported general payments places this provider in the 95th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 32 | $176,114 |
| LinzessLinaclotide | 160 | $96,498 |
| JardianceEmpagliflozin | 75 | $81,646 |
| FarxigaDapagliflozin Propanediol | 90 | $68,357 |
| JanuviaSitagliptin Phosphate | 84 | $67,157 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $51,702 |
| AptiomEslicarbazepine Acetate | 24 | $48,392 |
| JanumetSitagliptin Phos/Metformin Hcl | 65 | $48,238 |
| Chlorpromazine Hcl | 151 | $46,032 |
| TrulicityDulaglutide | 41 | $42,917 |
| OzempicSemaglutide | 27 | $36,568 |
| MyrbetriqMirabegron | 69 | $35,457 |
| XcopriCenobamate | 17 | $32,482 |
| MounjaroTirzepatide | 23 | $32,470 |
| VraylarCariprazine Hcl | 18 | $24,636 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Vraylar | $1,250 | $121,134178 claims |
| MerckJanuvia, Janumet | $684 | $115,395149 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Olanzapine | $1,022 | $85,552224 claims |
| Boehringer IngelheimJardiance | $356 | $81,64675 claims |
| AstraZenecaFarxiga | $770 | $68,35790 claims |
| GSKTrelegy Ellipta | $1,033 | $51,70254 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $27 | $48,39224 claims |
| Novo NordiskOzempic | $1,333 | $36,56827 claims |
| Astellas Pharma US IncMyrbetriq | $301 | $35,45769 claims |
| SK Life Science, Inc.Xcopri | $32 | $32,48217 claims |
| PfizerEliquis | $749 | $19,55016 claims |
| Johnson & JohnsonXarelto | $344 | $18,22926 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Gulfport
- Kathy KeimigGulfport$20K
- Jonathan HamiltonGulfport$16K
- Dimitrios DimitriadesGulfport$13K
- Matthew BosargeGulfport$10K
- Paul MatherneGulfport$9K
- Russell CarlisleWesson$1.6M
- Keith StokesLexington$654K
- Walter CarnahanSouthaven$146K
- Karen WhitneyWhitfield$117K
- Dava ClevelandJackson$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.